Across large nusinersen clinical trials with SMA types 1, 2 and presymptomatic infants (2 or 3 SMN2 copies), plasma phosphorylated neurofilament heavy chain (pNF-H) differentiated SMA individuals from healthy controls. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.